Bronze
Dxome strived to follow its slogan, “Everything about Dx(Diagnosis),” to provide products and services of high quality to improve the state of healthcare. We possess competitive BT and IT technologies and have integrated both technologies to commercialized precision diagnosis platform. Moreover, we developed NGS-based precision medicine products utilizing artificial intelligence and big data technologies to provide optimal treatment plans. In addition, as the industry leader, we are in-process of developing products for early detection, companion diagnostics, recurrence and post-treatment monitoring based on liquid biopsy to meet the needs of the markets. In order to meet the need of the rapidly changing field of medical diagnosis and international affairs, Dxome strives to perform ahead of the competitors by engaging in future-orientated product development, including detection of rare disorders and early diagnosis of solid tumors, companion diagnostics with targeted therapy, infectious disease and antibiotic resistance. Dxome looks forward to growing as an industry-leading company to provide technology and products that improves the quality of human healthcare. We look forward to your interest and support and forwards to the opportunities ahead of us.
With our Proprietary technology, we created an optimized and simplified product that is easy to use and produces results with high sensitivity and accuracy. In addition, the product is an all-in-one product that includes necessary components to produce and amplified libraries of interest. The Product also utilizes bioinformatics pipelines containing latest technology for precise data analysis and high-quality solution. NGS Series: DxLiquid / DxSeq DxLiquid, our ctDNA products, provides a comprehensive analysis for the diagnosis of genetic mutations in various cancers. Our panels analyze the data collected by integrating SNV, InDel, CNV, RNA-fusion, MSI (Microsatellite Instability), and TMB (Tumor Mutation Burden) information, enabling precise diagnosis of cancer at an early stage. DxSeq consists of reagent necessary to prepare the DNA for targeted sequencing and a cloud-based analysis platform that is easily accessible. Data from various hereditary disorders can be collected with NGS technology and the data obtained can be easily analyzed without the need of an expert by analysis the data using a large database. ▶ Features NGS Product - Minimization library prep steps - Hybridization method - High quality capture probes - High efficiency and reproducibility - High value biomarkers: Core genes included (HER2, EGFR, ALK, KRAS, NRAS, BRAF, BRCA1/2, KIT, IDH1/2, PDGFRA, MYC, MYCN and more) Bioinformatics - Cloud-based analysis system - Robus analysis: SNV, InDel, CNV, Fusion, Microsatellite instability(MSI), Tumor Mutation Burden TMB - Variant classification guideline automatically applied - Visualized and comprehensive report